15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Teva Pharma Industries Ltd ADR, 9 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $40.00 to $45.00, so the covering firms are broadly aligned. The average target of $41.78 sits 32% above the current $31.66. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.66 next quarter toward $3.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Strong Buy
Strong Buy00%
Buy9100%
Hold00%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Teva Pharma Industries Ltd ADR.
As of Jul, 9 of 9 firms rate TEVA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TEVA EPS & revenue forecast
EPS · NEXT QUARTER
$0.66
Range $0.25 – $0.76 · 9 analysts · -16% YoY
Next period, 9 analysts expect Teva Pharma Industries Ltd ADR to earn $0.66 a share (range $0.25 – $0.76), versus $0.78 a year earlier. Full-year consensus is $2.16, growing to $3.09 the year after.
REVENUE · NEXT QUARTER
$4.2B
Range $4.2B – $4.3B · 9 analysts · -5% YoY
Revenue is expected to reach $4.2B (range $4.2B – $4.3B), -5.1% year-over-year. Full-year consensus is $16.6B, rising to $17.2B next year.
Top analysts covering Teva Pharma Industries Ltd ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TEVA.
#1
Yatin Suneja
Guggenheim · Rank #28
Hold
No targeton TEVA
Overall win rate
52%
+ Follow
#2
David Amsellem
Piper Sandler · Rank #95
Buy
$42.00+32.7% to target
Overall win rate
50%
+ Follow
#3
Jason Gerberry
B of A Securities · Rank #136
Buy
$40.00+26.3% to target
Overall win rate
46%
+ Follow
#4
CS
Chris Schott
JP Morgan
Buy
No targeton TEVA
Coverage
—
+ Follow
#5
Ashwani Verma
UBS
Buy
$42.00+32.7% to target
Coverage
—
+ Follow
TEVA stock forecast FAQ
What is TEVA's average 12-month price target?+
The 9 analysts with a live target average $41.78 for Teva Pharma Industries Ltd ADR over the next 12 months, ranging from a $45.00 high to a $40.00 low.
Is TEVA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 9 analyst ratings, 9 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TEVA?+
The Street-high target is $45.00 (Truist Securities), and the Street-low is $40.00 (Barclays). The average of all 9 active targets is $41.78.
How many Wall Street analysts cover TEVA?+
9 analysts have an active rating on Teva Pharma Industries Ltd ADR, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering TEVA?+
Among analysts who currently cover TEVA, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Hold.
What is Teva Pharma Industries Ltd ADR's projected EPS for next quarter?+
The consensus estimate is $0.66 per share (range $0.25 – $0.76) across 9 analysts. Full-year EPS is projected at $2.16, rising to $3.09 the following year.
How much revenue is Teva Pharma Industries Ltd ADR expected to report next quarter?+
Consensus revenue is $4.2B (range $4.2B – $4.3B). Full-year revenue is projected at $16.6B, growing to $17.2B next year.
Have analysts been upgrading or downgrading TEVA lately?+
As of Jul, 9 of 9 firms rate TEVA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TEVA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
